Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pancreatic vein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Pancreatic vein. Displaying page 1 of 1.
    EudraCT Number: 2019-002196-34 Sponsor Protocol Number: Neo.Lu.Pa.NET Start Date*: 2019-11-07
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET)
    Medical condition: Resectable pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005141-16 Sponsor Protocol Number: NL75539.078.20 Start Date*: 2021-06-23
    Sponsor Name:Erasmus MC
    Full Title: Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study.
    Medical condition: non-metastatic resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000242-19 Sponsor Protocol Number: RHMGSU0241 Start Date*: 2018-04-13
    Sponsor Name:University Hospitals Southampton NHS Trust
    Full Title: Change in nutritional state and postoperative outcome following preoperative introduction of nutritional supplements and pancreatic enzymes in patients undergoing Whipple’s procedure for pancreatic...
    Medical condition: Patients undergoing Whipple’s procedure for pancreatic head tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10033644 Pancreaticoduodenectomy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000345-46 Sponsor Protocol Number: CRC2017_01 Start Date*: 2017-11-22
    Sponsor Name:CENTRO RICERCHE CLINICHE DI VERONA
    Full Title: A Phase II Study of Liposomial IrinoTecan (nal-IRI) with 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer ¿nITRo trial"
    Medical condition: Resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004987-91 Sponsor Protocol Number: 2020/ABM/01/00098 Start Date*: 2021-11-17
    Sponsor Name:Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
    Full Title: Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and progression – free survival in patients with pancreatic can...
    Medical condition: Unresectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003669-17 Sponsor Protocol Number: NEOPA Start Date*: 2013-12-17
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma (NEOPA).
    Medical condition: Non-metastasized, adenocarcinoma of the pancreatic head/uncinate process or body of pancreas that was treated with extended pancreatic head/body resection larger than 2 cm in size (≥cT2) and/or in ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021477-36 Sponsor Protocol Number: NEOPAC Start Date*: 2015-01-30
    Sponsor Name:Gesellschaft für Studienmanagement und Onkologie mbH
    Full Title: Adjuvant chemotherapy versus NEOadjuvant gemcitabine/ oxaliplatin plus adjuvant gemcitabine in resectable PAncreatic Cancer: a randomized multicenter phase III study
    Medical condition: resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033608 Pancreatic cancer resectable LLT
    17.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005530-42 Sponsor Protocol Number: imPaCT-PRO-01 Start Date*: 2021-12-07
    Sponsor Name:Institute of Molecular Medicine and Biomedical Research (IMBE)
    Full Title: The impact of Thromboprophylaxis on Progression Free Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer & Tinzaparin Prospective (imPaCT-PRO) study
    Medical condition: Thromboprophylaxis in patients with advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10043607 Thrombosis PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068067 Tumour thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001028-21 Sponsor Protocol Number: ABCSG_P01 Start Date*: 2013-05-17
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: P01 - A prospective, randomized, multicenter trial of additional radiochemotherapy to neoadjuvant chemotherapy in patients with locally advanced pancreatic adenocarcinoma
    Medical condition: locally advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004523-19 Sponsor Protocol Number: TIP0305 Start Date*: 2008-02-08
    Sponsor Name:Área de Trasplante y Terapia Celular - Hospital Central de Asturias
    Full Title: Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant patients.
    Medical condition: Type-I Diabetes Mellitus in renal trasplant patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061835 pt
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003085-12 Sponsor Protocol Number: ANT-008 Start Date*: 2022-05-10
    Sponsor Name:Anthos Therapeutics
    Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding i...
    Medical condition: venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000614-64 Sponsor Protocol Number: VIRUSNET201401 Start Date*: 2015-12-17
    Sponsor Name:Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University
    Full Title: Study of recombinant adenovirus in patients with neuroendocrine neoplasms; safety and efficacy
    Medical condition: Neuroendocrine neoplasms (NENs) is a heterogeneous group with varying symptoms, tumor biology and treatment response. NENs may occur in any organ, most commonly they are observed in the gastroente...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012584-34 Sponsor Protocol Number: GRASPALL2009-06 Start Date*: 2010-01-06
    Sponsor Name:ERYTECH Pharma
    Full Title: A multicentre, open, randomized, Phase II/III study, evaluating efficacy and safety of erythrocytes encapsulating L-Asparaginase (GRASPA®) versus reference L-asparaginase treatment in combination w...
    Medical condition: Acute Lymphoblastic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005731-23 Sponsor Protocol Number: N21PMA Start Date*: 2022-10-25
    Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
    Full Title: Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study.
    Medical condition: adenocarcinoma of the colon or rectum
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 14:33:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA